Advanced Therapy of Prostate Disease

1 Epidemiology of Prostate Cancer: an Overview
2 Epidemiology of Prostate Cancer in African Americans
3 Epidemiology of Prostate Cancer in Africa
4 Prostate Cancer among the Chinese: Pathologic, Epidemiologic,
and Nutritional Considerations
5 Epidemiology of Prostate Cancer in Jamaicans
6 Epidemiology of Prostate Cancer in Hispanic Americans
7 Assessment of Risk of Prostate Cancer: Algorithms for
Diagnosis, Staging, and Prognosis
8 Molecular Factors in the Assessment of Prostate Cancer Risk
9 Screening for Prostate Cancer: an Overview
10 The Optimal Diagnostic Tool: Assessment of Diagnostic
Modalities to Detect Early
Prostate Cancer
11 Screening for Prostate Cancer: the Case for Screening
12 Screening for Prostate Cancer: the Argument for Caution
13 Natural History of Localized Adenocarcinoma of the Prostate
14 Prostate Physiology and Regulation
15 Pathobiology of Prostate Diseases: an Update
16 Models of Prostate Cancer
17 Diagnosis of Prostate Cancer
18 Staging of Prostate Cancer
19 Radical Prostatectomy: Patient Preparation
20 Stage T1a Prostate Cancer: the Case for Treatment
21 T1b-T2NxM0: the Case for Observation
22 Radical Retropubic Prostatectomy for Clinical Stage T1b-T2
Prostate Cancer
23 Radical Perineal Prostatectomy
24 Continence-Enhancing Modifications for Radical Prostatectomy
25 T1-T2NxM0: the Case for External Radiotherapy
26 Permanent Low-Dose-Rate Interstitial Brachytherapy
27 T1b-T2NxM0: a Case for Hormonal Therapy?
28 Role of Cryosurgery in the Treatment of Prostate Cancer
29 Should T1c Disease Be Treated Differently from T2 Disease?
30 T3-T4NxM0: the Case for Observation
31 T3-T4NxM0: the Case for Radiotherapy
32 Clinical-Pathologic T3NxM0 Prostate Cancer: the Case for
Surgery
33 Node-Positive Prostate Cancer: the Case for Observation
34 TxN+M0: the Case for Radiotherapy
35 TxN+M0 Disease: the Case for Early Hormonal Therapy and
Surgery
36 TxNxM1: the Case for Monotherapy
37 TxNxM1: the Case for Total Androgen Deprivation
38 Is Early Hormonal Therapy Preferable?
39 Staging Failures of Initial Therapy
40 Management of Prostate-Specific Antigen Failure after
Definitive Therapy forClinically Localized Prostate Cancer
41 Management of Local Failure following Treatment of Localized
Prostate Cancer
42 Secondary Hormonal Therapy
43 Management of Hormone-Refractory Prostate Cancer:
Chemotherapy and Immunotherapy
44 The Artificial Genitourinary Sphincter
45 Collagen Therapy for Postprostatectomy Incontinence
46 Management of Complications of Therapy: Erectile Dysfunction
47 Anorectal Complications of Prostate Surgery
48 Chemoprevention of Cancer of the Prostate
49 Prostate Cancer: Management of Complications of the Disease
and Its Therapy
50 Randomized Clinical Trials in Prostate Cancer
51 Hormonal and Cellular Aspects of Benign Prostatic Hyperplasia
52 Need for Urodynamics and Other Testing
53 Minimal Essential Diagnostic Testing
54 Pathophysiology of Bladder Outlet Obstruction and Voiding
Dysfunction
55 Prevention of the Progression and Long-Term Complications of
Benign Prostatic Hyperplasia
56 Benign Prostatic Hyperplasia:When to Intervene
57 Preprocedural Evaluation/Preparation
58 Options for Treatment of Benign Prostatic Hyperplasia: Alpha-
Blockers
59 5 Alpha-Reductase Inhibitors
60 Transurethral Needle Ablation of the Prostate for Treatment
of Benign Prostatic Hyperplasia
61 Options for Treatment: Contact
62 Free Beam Laser Prostatectomy
63 Transurethral Resection of the Prostate
64 Transurethral Incision of the Prostate
65 Open Prostatectomy in the Management of Benign Prostatic
Hyperplasia
66 Phytotherapy in the Treatment of Benign Prostatic Hyperplasia
67 Prostatitis: Pathophysiology
68 Prostatitis: Diagnosis
69 Prostatitis: Differential Diagnosis, Classification, and
Conventional Treatment Strategies
70 Prostatitis: Factors Influencing